Orographic Financial Advisors LLC bought a new stake in shares of McKesson Corporation (NYSE:MCK – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 903 shares of the company’s stock, valued at approximately $782,000.
A number of other institutional investors and hedge funds have also made changes to their positions in MCK. Horizon Investments LLC boosted its position in shares of McKesson by 125.4% during the fourth quarter. Horizon Investments LLC now owns 8,679 shares of the company’s stock valued at $7,119,000 after buying an additional 4,828 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of McKesson by 18.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 31,526 shares of the company’s stock worth $25,860,000 after buying an additional 4,964 shares during the period. HF Advisory Group LLC lifted its stake in shares of McKesson by 2,069.6% during the 4th quarter. HF Advisory Group LLC now owns 44,910 shares of the company’s stock worth $36,839,000 after acquiring an additional 42,840 shares during the last quarter. Concurrent Investment Advisors LLC lifted its stake in shares of McKesson by 62.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 3,158 shares of the company’s stock worth $2,590,000 after acquiring an additional 1,219 shares during the last quarter. Finally, Adelphi Trust Co purchased a new position in McKesson during the 4th quarter valued at $1,177,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at McKesson
In other news, EVP Thomas L. Rodgers sold 699 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $735.27, for a total transaction of $513,953.73. Following the transaction, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,667,592.36. This trade represents a 23.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Brian S. Tyler sold 8,463 shares of McKesson stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the transaction, the chief executive officer directly owned 5,919 shares in the company, valued at approximately $4,697,081.64. The trade was a 58.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 28,748 shares of company stock worth $22,262,035 over the last quarter. 0.06% of the stock is currently owned by company insiders.
Key McKesson News
- Positive Sentiment: McKesson continues to benefit from expectations for earnings growth. Its latest reported quarter exceeded EPS estimates, and management’s fiscal 2027 outlook calls for earnings of $43.80–$44.60 per share. McKesson earnings expected to grow
- Neutral Sentiment: McKesson’s chief legal officer is leaving to take the same role at luxury home-furnishings company RH. The move is not necessarily an operating concern, but executive turnover may attract investor attention. RH hires McKesson chief legal officer
- Negative Sentiment: A Zacks preview said McKesson lacks the combination of favorable earnings expectations and estimate-revision momentum that typically signals a likely earnings beat. That caution may have pressured the stock ahead of results, particularly after its strong run toward its 52-week high. McKesson earnings preview
- Negative Sentiment: The latest market recap noted that McKesson declined while the broader market advanced, indicating relative weakness rather than a sector-wide healthcare selloff. Investors appear focused on whether upcoming results can justify the company’s elevated valuation. McKesson stock market recap
Analysts Set New Price Targets
Several equities analysts have commented on the company. Weiss Ratings downgraded McKesson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, July 7th. Wells Fargo & Company cut their price target on shares of McKesson from $925.00 to $812.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $875.00 price target on shares of McKesson in a research note on Friday, May 8th. TD Cowen lowered their price objective on shares of McKesson from $1,012.00 to $989.00 and set a “buy” rating for the company in a research report on Tuesday, July 21st. Finally, William Blair began coverage on shares of McKesson in a research note on Tuesday, April 28th. They issued an “outperform” rating on the stock. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $962.67.
Check Out Our Latest Stock Report on MCK
McKesson Trading Down 2.4%
Shares of McKesson stock opened at $867.05 on Friday. The firm has a market cap of $101.51 billion, a P/E ratio of 22.54, a P/E/G ratio of 1.46 and a beta of 0.31. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00. The stock’s fifty day moving average price is $788.86 and its 200-day moving average price is $840.10.
McKesson (NYSE:MCK – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The company had revenue of $96.30 billion during the quarter, compared to analyst estimates of $101.35 billion. During the same period in the prior year, the firm earned $10.12 earnings per share. The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Analysts forecast that McKesson Corporation will post 44.28 earnings per share for the current year.
McKesson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be issued a $0.94 dividend. The ex-dividend date is Tuesday, September 1st. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. This is an increase from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio (DPR) is presently 9.77%.
About McKesson
McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.
The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.
Read More
- Five stocks we like better than McKesson
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
